Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

Sigma Planning Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Operator Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.26% to $470.36 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.16% ...

Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.27%.

At the heart of this biotech boom lies Vertex Pharmaceuticals, a trailblazer that has played a pivotal role in transforming medical landscapes and reshaping patient lives. From groundbreaking ...

BOSTON - Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated (NASDAQ:VRTX) has released new data demonstrating significant progress in its clinical trials for kidney diseases, including IgA ...

So when a business like Vertex Pharmaceuticals (NASDAQ: VRTX) releases some new data on a potential blockbuster that could be just a few months away from being approved for sale, it's a big ...